Skip to main content
. 2017 Dec 3;2017:1683060. doi: 10.1155/2017/1683060

Table 3.

Efficacy results of VICTOR trial in the TNBC population.

Variable Overall
N = 28
Clinical benefit rate (CR + PR + SD ≥ 24 weeks) n/N (%) 10/28 (35.7)
[95%  CI] [18.6–55.9]
Kaplan-Meier estimate of median duration of clinical benefit (months) 11.3
Disease control rate (CR + PR + SD) n/N 15/28 (53.6%)
Kaplan-Meier estimate of median duration of response in disease control (months) 7.4
Kaplan-Meier estimate of median PFS (months) 4.7